[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100458582":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":33,"centralContacts":37,"locations":48,"responsibleParty":70,"collaborators":73,"id":76,"slug":77,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":42,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":84,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":42,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":51,"whyStopped":42,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Saskatchewan Health Authority - Regina Area","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Iron Isomaltoside\u002Fferric derisomaltose","ACTIVE_COMPARATOR","route: intravenous Dosage: 1000-1500 mg (100mg\u002FmL), max dose 20mg\u002Fkg Frequency: max dose 1000 mg, if further doses required, must receive dosage divided Duration: one infusion or two infusions (dose dependent)",[13],"Drug: Iron Isomaltoside 1000, ferric derisomaltose",{"label":15,"type":10,"description":16,"interventionNames":17},"Iron Sucrose","Route: Intravenous Dosage: 100 mg\u002FmL (maximum 300 mg per dose) Frequency: up to 3 doses per week or 1000 mg per week maximum Duration: until iron needs reached by simplified table",[18],"Drug: Iron sucrose",[20,27],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Iron Isomaltoside 1000, ferric derisomaltose","iron isomaltoside 20 mg\u002FmL",[9],[26],"Monoferric DIN 22477777",{"type":21,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"Iron sucrose","iron sucrose 100 mg\u002FmL",[15],[32],"iron sucrose DIN 02502917",[34],{"name":35,"affiliation":5,"role":36},"Ryan Lett, MD, FRCPC","PRINCIPAL_INVESTIGATOR",[38,44],{"name":39,"role":40,"phone":41,"phoneExt":42,"email":43},"Ryan Lett, MD FRCPC","CONTACT","306-766-3491",null,"ryan.lett@saskhealthuauthority.ca",{"name":45,"role":40,"phone":46,"phoneExt":42,"email":47},"Sarah Smith, MD, BSc","306-352-4963","sarah.Naden.Smith@gmail.com",[49],{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"Regina General Hospital","RECRUITING","Regina","Saskatchewan","S4P 0W5","Canada","CA",{"type":58,"coordinates":59},"Point",[60,61],-104.6178,50.45008,{"lat":61,"lon":60},[64,68],{"name":65,"role":40,"phone":66,"phoneExt":42,"email":67},"Alicia Hanowski, BScN","3067663134","alicia.hanowski@saskhealthauthority.ca",{"name":35,"role":40,"phone":41,"phoneExt":42,"email":69},"ryan.lett@saskhealthauthority.ca",{"type":36,"investigatorFullName":71,"investigatorTitle":72,"investigatorAffiliation":5,"oldNameTitle":42,"oldOrganization":42},"Ryan Lett","Physician Lead Patient Blood Management Department",[74],{"name":75,"class":6},"Saskatchewan Centre for Patient-Oriented Research","100458582","phase-3-ferric-derisomaltose-iron-isomaltoside-versus-iron-sucrose-for-treatment-of-iron-deficiency-in-pregnancy-100458582",false,"NCT05251493","Ferric Derisomaltose (Iron Isomaltoside) Versus Iron Sucrose for Treatment of Iron Deficiency in Pregnancy","Intravenous Iron Isomaltoside Versus Iron Sucrose for Treatment of Iron Deficiency in Pregnancy: A Randomized Comparative Trial","Inclusion Criteria:\n\n* 18 years of age and over\n* Pregnancy with Gestational age ≥13 weeks\n* Iron deficiency anemia defined as:\n* Hemoglobin less than or equal to 110g\u002FL and\n* Serum ferritin less than 30ng\u002FmL or\n* Iron Saturation (Iron\u002FTIBC) less than 20%\n* Willing to participate and attend all planned follow up visits\n* Willing to sign informed consent form\n* Willing to attend appointments for iron infusion and follow up visits\n* Willing to attend all planned bloodwork appointments\n\nExclusion Criteria:\n\n* Pregnancy GA less than 13 weeks\n* History of anemia caused by thalassemia or other haematologic disorder other than iron deficiency anemia ,\n* Known serious hypersensitivity to other parental iron products\n* Iron overload or disturbances in utilization of iron (i.e, haemochromatosis and haemosiderosis)\n* Decompensated liver cirrhosis or active hepatitis\n* History of multiple allergies\n* Active acute or chronic infections\n* Treated with IV iron products or blood transfusion within 4 weeks prior to inclusion\n* Current participation in any other interventional trial\n* Multiple gestation pregnancy\n* Significant comorbidities (asthma requiring daily therapy or other lung diseases)\n* Heart disease\n* Kidney disease\n* Rheumatologic disease\n* Cancer\n* Known hypersensitivity to iron sucrose or any excipients\n* Known hypersensitivity to iron isomaltoside or any excipients.",true,"FEMALE","18 Years","50 Years",{"count":88,"type":89},280,"ESTIMATED","INTERVENTIONAL",[92],"PHASE3","Ion deficiency anemia (IDA) is associated with poor neonatal outcomes and maternal morbidity. Iron replacement may be done with oral iron or intravenous iron, with intravenous iron being utilized later in pregnancy or if there is an inadequate response to oral iron in the first trimester. In Canada, iron sucrose has been used, however iron isomaltoside is as safe as other formulations of IV iron but can replete iron stores with a single visit. Replenishing iron stores reduces both maternal and neonatal risks and is supported by current guidelines. Iron status may play a role in depression, as well as anemia, bleeding and blood transfusion.\n\nThe goal of this clinical trial:\n\n* Correct IDA with fewer visits and less impact on the healthcare system\n* Improve the health and well being of all pregnant women who are experiencing moderate to severe iron deficiency anemia.",[95],"Iron Deficiency Anaemia in Childbirth",[97,98],"quality of life","anemia","2025-05-12",{"date":101,"type":102},"2025-05-15","ACTUAL",{"date":104,"type":102},"2022-06-06",{"date":106,"type":89},"2027-02-28",{"name":5,"class":6},1]